2020
Targeted Therapies in Advanced Gastric Cancer
Patel TH, Cecchini M. Targeted Therapies in Advanced Gastric Cancer. Current Treatment Options In Oncology 2020, 21: 70. PMID: 32725377, DOI: 10.1007/s11864-020-00774-4.Peer-Reviewed Original ResearchConceptsGastric cancerMetastatic diseaseClinical trialsVascular endothelial growth factor receptor inhibitorDeath ligand 1 (PD-L1) statusEndothelial growth factor receptor inhibitorImmune checkpoint inhibitor pembrolizumabHuman epidermal growth factor 2Epidermal growth factor 2Growth factor receptor inhibitorsBackbone of therapyCheckpoint inhibitor pembrolizumabCombination immune therapyThird-line settingFirst-line settingSecond-line settingAddition of trastuzumabPD-L1 statusAdvanced gastric cancerMetastatic gastric cancerHER2-positive tumorsSquamous cell carcinomaFuture clinical trialsNumerous clinical trialsStandard of care
2019
Challenges with Novel Clinical Trial Designs: Master Protocols
Cecchini M, Rubin EH, Blumenthal GM, Ayalew K, Burris HA, Russell-Einhorn M, Dillon H, Lyerly HK, Reaman GH, Boerner S, LoRusso PM. Challenges with Novel Clinical Trial Designs: Master Protocols. Clinical Cancer Research 2019, 25: 2049-2057. PMID: 30696689, DOI: 10.1158/1078-0432.ccr-18-3544.Peer-Reviewed Original ResearchConceptsClinical trial designPlatform trialsMaster protocolsUmbrella trialsTrial designBasket trialsNovel clinical trial designsPanel of expertsMultiple investigational agentsInnovative clinical trial designsNovel clinical trialsInstitutional review boardDifferent tumor typesExpansion cohortInvestigational agentsSame histologyClinical trialsTumor typesBasket studyPatientsReview boardTrialsDrug development processDrug assessmentHistology